Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 2Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 26Lymphoma 24Lymphoma, Follicular 22Leukemia, Lymphocytic, Chronic, B-Cell 22Lymphoma, Mantle-Cell 21Lymphoma, Large B-Cell, Diffuse 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 20Lymphoma, Large-Cell, Immunoblastic 19Burkitt Lymphoma 18Hodgkin Disease 16Lymphoma, B-Cell, Marginal Zone 14Leukemia 13Multiple Myeloma 9Neoplasms, Plasma Cell 7Leukemia, Myeloid, Acute 6Waldenstrom Macroglobulinemia 5Recurrence 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Leukemia, Myeloid, Chronic-Phase 4Congenital Abnormalities 4Myelodysplastic Syndromes 3Lymphoma, T-Cell, Cutaneous 3Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 3Leukemia, Myeloid, Accelerated Phase 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Dendritic Cell Sarcoma, Interdigitating 3Blast Crisis 3Testicular Neoplasms 2Primary Myelofibrosis 2Pdgfra-Associated Chronic Eosinophilic Leukemia 2

Interventions

Dexamethasone 10fludarabine phosphate 9Melphalan 9fludarabine 8Whole-Body Irradiation 7Peripheral Blood Stem Cell Transplantation 7Lenalidomide 7Cyclophosphamide 7Mycophenolic Acid 6Bortezomib 6Tacrolimus 5Calcium Dobesilate 4filanesib 3dexamethasone acetate 3dexamethasone 21-phosphate 3daratumumab 3carfilzomib 3auricularum 3Stem Cell Transplantation 3Sirolimus 3Filgrastim 3liposomal doxorubicin 2ixazomib 2Steroids 2Injections, Subcutaneous 2Granulocyte Colony-Stimulating Factor 2Etoposide 2Cytarabine 2Cyclosporine 2Carmustine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Leukemia, Plasma Cell × Carmustine × Other hematologic neoplasm × Clear all
NCT02504359 2020-11-23

Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma

OHSU Knight Cancer Institute

Phase 1 Completed
11 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Neoplasms, Plasma Cell

NCT01008462 2019-06-11

Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

Fred Hutchinson Cancer Center

Phase 2 Completed
16 enrolled 15 charts
LymphoidOther hematologic neoplasmPlasma cell

Chromosome 17 deletion, Hodgkin Disease, Leukemia, Plasma Cell, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, T-Cell, Leukemia, Prolymphocytic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡